Healthcare data analytics company Health Catalyst (NASDAQ: HCAT) announced better-than-expected revenue in Q4 CY2025, but sales fell by 6.2% year on year to $74.68 million. On the other hand, next quarter’s revenue guidance of $69 million was less impressive, coming in 7.9% below analysts’ estimates. Its non-GAAP profit of $0.08 per share was 16.1% below analysts’ consensus estimates.
Is now the time to buy Health Catalyst? Find out by accessing our full research report, it’s free.
Health Catalyst (HCAT) Q4 CY2025 Highlights:
- Revenue: $74.68 million vs analyst estimates of $74.04 million (6.2% year-on-year decline, 0.9% beat)
- Adjusted EPS: $0.08 vs analyst expectations of $0.10 (16.1% miss)
- Adjusted EBITDA: $13.79 million vs analyst estimates of $13.37 million (18.5% margin, 3.1% beat)
- Revenue Guidance for Q1 CY2026 is $69 million at the midpoint, below analyst estimates of $74.91 million
- EBITDA guidance for Q1 CY2026 is $7.5 million at the midpoint, below analyst estimates of $11.26 million
- Operating Margin: -115%, down from -22% in the same quarter last year
- Free Cash Flow was $4.50 million, up from -$5.27 million in the previous quarter
- Market Capitalization: $131.6 million
“We closed 2025 with solid performance across our business, including total revenue of $311.1 million and Adjusted EBITDA of $41.4 million,” said Ben Albert, CEO of Health Catalyst “In 2026, we are focused on the future and on positioning Health Catalyst for long‑term success.
Company Overview
Built on its "Health Catalyst Flywheel" methodology that emphasizes measurable outcomes, Health Catalyst (NASDAQ: HCAT) provides data and analytics technology and services that help healthcare organizations manage their data and drive measurable clinical, financial, and operational improvements.
Revenue Growth
A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last five years, Health Catalyst grew its sales at a 10.5% compounded annual growth rate. Though this growth is acceptable on an absolute basis, we need to see more than just topline growth for the software sector, which can display significant earnings volatility. This means our bar for the sector is particularly high, reflecting the non-essential and hit-driven nature of the products and services offered. Additionally, five-year CAGR starts around Covid, when revenue was depressed then rebounded.
We at StockStory place the most emphasis on long-term growth, but within software, a half-decade historical view may miss recent innovations or disruptive industry trends. Health Catalyst’s recent performance shows its demand has slowed as its annualized revenue growth of 2.5% over the last two years was below its five-year trend. We’re wary when companies in the sector see decelerations in revenue growth, as it could signal changing consumer tastes aided by low switching costs. 
This quarter, Health Catalyst’s revenue fell by 6.2% year on year to $74.68 million but beat Wall Street’s estimates by 0.9%. Company management is currently guiding for a 13.1% year-on-year decline in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to decline by 2.9% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and implies its products and services will face some demand challenges.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Customer Acquisition Efficiency
The customer acquisition cost (CAC) payback period represents the months required to recover the cost of acquiring a new customer. Essentially, it’s the break-even point for sales and marketing investments. A shorter CAC payback period is ideal, as it implies better returns on investment and business scalability.
Health Catalyst’s recent customer acquisition efforts haven’t yielded returns as its CAC payback period was negative this quarter, meaning its incremental sales and marketing investments outpaced its revenue. The company’s inefficiency indicates it operates in a highly competitive environment where there is little differentiation between Health Catalyst’s products and its peers.
Key Takeaways from Health Catalyst’s Q4 Results
It was encouraging to see Health Catalyst beat analysts’ EBITDA expectations this quarter. On the other hand, its revenue guidance for next quarter missed and its EBITDA guidance for next quarter fell short of Wall Street’s estimates. Overall, this was a weaker quarter. The stock traded down 10.4% to $1.60 immediately following the results.
Health Catalyst didn’t show it’s best hand this quarter, but does that create an opportunity to buy the stock right now? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).
